Literature DB >> 7347111

Computed tomography, angiography and ultrasound in staging of renal carcinoma.

W Karp, L Ekelund, G Olafsson, A Olsson.   

Abstract

Preoperative evaluation of the extent of the renal tumor is of value in determining the prognosis of the patient and the most suitable therapy. CT and angiography were reviewed in 27 cases of renal carcinoma to evaluate tumor involvement of lymph nodes, renal vein, vena cava, and the perinephric space. In 26 of these cases the ultrasound examination was similarly reviewed. Comparison of ultrasound, CT, and angiography demonstrated that staging of renal tumors with ultrasound is mainly limited by its inability to demonstrate extrarenal infiltration. Both CT and ultrasound proved reliable in the demonstration of tumor spread to the renal vein and inferior vena cava. CT and angiography were equally effective in the evaluation of tumor extension; since CT is easier to perform, less invasive and less time consuming than angiography it should be the primary method for staging of renal neoplasms. Angiography offers detailed information on the vascular supply of the tumor important for the choice of surgical approach and should be performed only on special indications.

Entities:  

Mesh:

Year:  1981        PMID: 7347111     DOI: 10.1177/028418518102200601

Source DB:  PubMed          Journal:  Acta Radiol Diagn (Stockh)        ISSN: 0567-8056


  2 in total

1.  Long term survival in a young girl with renal cell carcinoma.

Authors:  M Ray; R K Marwaha; A Trehan; K L Narasimhan
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

2.  Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry.

Authors:  Ozgur Akgul; Hatice Bodur; Sebnem Ataman; Fatma Gul Yurdakul; Erhan Capkin; Gulcan Gurer; Ilhan Sezer; Mehmet Tuncay Duruoz; Meltem Alkan Melikoglu; Hasan Fatih Cay; Aylin Rezvani; Ilker Yagci; Feride Gogus; Ayhan Kamanli; Remzi Cevik
Journal:  Rheumatol Int       Date:  2020-08-19       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.